Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EMPAGLIFLOZIN Cause Acute kidney injury? 1,023 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,023 reports of Acute kidney injury have been filed in association with EMPAGLIFLOZIN (Jardiance). This represents 2.8% of all adverse event reports for EMPAGLIFLOZIN.

1,023
Reports of Acute kidney injury with EMPAGLIFLOZIN
2.8%
of all EMPAGLIFLOZIN reports
72
Deaths
751
Hospitalizations

How Dangerous Is Acute kidney injury From EMPAGLIFLOZIN?

Of the 1,023 reports, 72 (7.0%) resulted in death, 751 (73.4%) required hospitalization, and 230 (22.5%) were considered life-threatening.

Is Acute kidney injury Listed in the Official Label?

Yes, Acute kidney injury is listed as a known adverse reaction in the official FDA drug label for EMPAGLIFLOZIN.

What Other Side Effects Does EMPAGLIFLOZIN Cause?

Diabetic ketoacidosis (3,644) Fungal infection (1,941) Blood glucose increased (1,797) Euglycaemic diabetic ketoacidosis (1,769) Weight decreased (1,661) Urinary tract infection (1,439) Ketoacidosis (1,411) Dizziness (1,372) Nausea (1,333) Vomiting (1,201)

What Other Drugs Cause Acute kidney injury?

OMEPRAZOLE (19,260) ESOMEPRAZOLE (18,678) LANSOPRAZOLE (16,359) PANTOPRAZOLE (15,961) METFORMIN (11,361) FUROSEMIDE (7,984) DEXLANSOPRAZOLE (7,599) VANCOMYCIN (4,018) TACROLIMUS (4,005) RIVAROXABAN (3,735)

Which EMPAGLIFLOZIN Alternatives Have Lower Acute kidney injury Risk?

EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\METFORMIN EMPAGLIFLOZIN vs EMSAM EMPAGLIFLOZIN vs EMTRICITABINE

Related Pages

EMPAGLIFLOZIN Full Profile All Acute kidney injury Reports All Drugs Causing Acute kidney injury EMPAGLIFLOZIN Demographics